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Highlights 
 TLRs are critical in systemic sclerosis 
 Activation of TLRs can be mediated by dangers signals from damaged cells 
 DAMPs may mediate fibrosis via TLR-dependant release of TIMPs 
 
 
 
 
Abstract 
Pattern Recognition Receptors are critical receptors that elicit an immune response upon their 
activation that culminates in activation of NF-KB and cytokine secretion. Key among these receptors 
are the Toll-Like Receptors (TLRs). These evolutionary conserved receptors form a key part in the 
defence against various pathogens and comprise a key part of the innate immune system. Systemic 
sclerosis is an autoimmune disease in which a breach of tolerance has occurred and leads to 
fulminant autoimmunity, dysregulated cytokines, pro-fibrotic mediators and activation of fibroblasts 
leading to fibrosis via collagen deposition. It has become apparent in recent years that the innate 
immune system and specifically TLRs are important in disease pathogenesis; responding to internal 
ligands to initiate an innate immune response ultimately leading to release of a variety of factors 
that initiate and perpetuate fibrosis. This review will examine the recent evidence of TLR signalling in 
systemic sclerosis and the internal danger associated molecules that may mediate the fibrotic 
cascade. Evaluation of their contribution to disease in systemic sclerosis and possible therapeutic 
targeting will be discussed.  
Introduction 
A major mechanism of innate immunity is the activation of a group of Pattern Recognition Receptors 
by molecules on specific pathogens. Toll-Like Receptors (TLRs) are a germline-encoded group of 
pattern recognition receptors that share high homology with the Toll gene in fruit flies and are found 
in eukaryotes and plants [1]. These TLRs recognise patterns on microbial species and internal 
damage associated molecular patterns that elicit an immune response without maintaining 
immunological memory. TLRs are widely and selectively expressed in multiple cell types including 
immune cells such as macrophages but also non immune cells such as epithelial cells and fibroblasts. 
They can respond to signalling via a variety of different cell types and a variety of different ligands 
either of endogenous origin, in the case of Danger Associated Molecular Patterns (DAMPs), or 
microbial origin. It is now widely acknowledged that as well as playing a role in multiple disease 
states TLRs play a primary role in fibrosis and systemic sclerosis. In terms of fibrosis, they can play a 
role via modulation through multiple cell types including macrophages.  Understanding the 
pathogenesis of systemic sclerosis and the role that TLRs play in this has been difficult but recent 
advances in molecular immunological research and the advent of new molecular techniques has 
helped uncover their roles in the disease. What are the physiological and non-physiological ligands 
that mediate activation to TLRs in the context of fibrosis is a key question. The cellular component of 
skin fibrosis comprises fibroblasts, endothelial cells, pericytes and macrophages, all of which express 
PRRs [2] (Table 1). 
Systemic Sclerosis (SSc) is an idiopathic autoimmune connective tissue disease that carries three 
hallmarks: vascular damage, inflammation and cytokine dysregulation and fibrosis [3]. The most 
obvious hallmark is skin fibrosis. Fibrosis is mainly in the skin but can also be present in the lungs and 
heart. To date the only disease modifying therapy found to regress the fibrosis is autologous stem 
cell transplant confirming the key role of the immune system in fibrosis, as there is an increased 
Tregulatory compartment after transplant and also alterations in the Th1/Th2 balance, with a skew 
toward a Th1 phenotype [4, 5] and a reduction post-transplant in autoantibodies [6]. Emerging 
evidence has suggested that the activation of the immune system in SSc may have an infectious 
basis or endogenous DAMPs [7]. Activation of the immune system and TLR triggering culminates in 
the release of pro-inflammatory and also pro-fibrotic mediators that ultimately results in the 
activation of a fibroblast to a myofibroblast with the release of copious amounts of Extracellular 
Matrix (ECM) and therefore fibrosis. Fibroblasts themselves also express TLRs, albeit at lower 
expression, and themselves are targets for TLR ligands. An explosion of recent interest in this area 
has identified molecular pathways that underpin TLR regulation and in SSc a variety of TLR ligands 
have been identified. The review aims to give an overview of the role of TLRs in SSc and propose 
areas for therapeutic intervention.  
TLRs signalling 
TLRs were first discovered in Drosophila melanogaster and ‘’Toll’’ relates to a mutant gene encoding 
a receptor involved in embryonic development. Cells endowed with TLRs have an ability to respond 
to various ligands endogenous and microbial. TLRs are transmembrane proteins that contain an 
extracellular leucine rich repeat and a cytosolic Toll-IL-1 receptor domain (TIR) that is responsible for 
downstream signalling [8]. The activation of TLRs culminates in NF-KB activation and pro-
inflammatory cytokine release. TLRs recruit adaptor proteins that include MyD88, Mal, Trif and Tram 
[9]. MyD88 is ultilized by all the TLRs with the exception of TLR3. TLRs are found primarily in the 
cellular membrane and some are found intracellularly upon endosomes making them uniquely 
placed to respond to their ligands. Negative regulation of TLR activation is important to restrain 
inappropriate inflammation and this occurs through microRNAs. MicroRNAs are epigenetic 
regulators of gene expression by negatively regulating gene expression by binding to the 3’UTR of 
target mRNAs [10]. One of the most inducible microRNAs after LPS stimulation is microRNA155 that 
elevates to negatively regulate the immune response by targeting SHIP1 [11]. Mice with genetic 
ablation of microRNA155 have autoimmunity, indicating a critical role in negative regulation [11]. Of 
course other epigenetic modifiers could also negatively regulate TLRs such as histone modification. 
Negative regulation. Another negative regulator of TLR signalling is Suppressor of Cytokine Signalling 
1 (SOCS1) [12]. SOCS1 is rapidly induced upon TLR4 stimulation to negatively regulate the TLR 
signalling and overexpression of SOCS1 results in attenuated NF-KB transcriptional activity [12] and 
SOS1 gene deleted mice challenged with LPS have increased mortality [12]. Also AKt1 has been 
found to regulate the response to TLR agonists and endotoxin tolerance through its regulation of 
SOCS1 expression by reducing the expression of SOCS1 via its regulator microRNA miR155 [13].  
Stranger Danger 
The danger theory proposed by Matzinger states that the immune system responds to danger rather 
than just non-self [14]. Five years earlier Charles Janeway had suggested that the immune system is 
activated by conserved patterns in different microorganisms.  
It is more than 20 years since Matzinger proposed the danger theory that explains why immune 
responses occur in organ transplants, tumours, trauma injuries and autoimmune disorders all 
without a microbial component.  This model suggests that proteins normally not seen by the 
immune system ‘’hidden’’ intracellularly are released upon damage or ‘’stress’’ to the cells and 
evoke an immune response.  This was for years a theoretical model until HMGB-1 was confirmed to 
be a DAMP [15]. Arguably HMGB-1 is the proto-typical DAMP. HMGB-1 is a nuclear protein that 
normally resides in the nucleus but can also be released upon which it can engage the LPS receptor 
TLR4 leading to inflammation  [15]. This nascent field is growing rapidly with new DAMPs being 
described yearly and now included mitochondrial DAMPs released via trauma [16] This may not be 
as surprising as it first seems as mitochondria are endosymbionts derived from ancient bacteria 
engulfed by archezoan cells approximately 2 billion years ago. And like bacteria, have their own 
circular DNA that replicates independently of nuclear DNA. Indeed, they also have similar 
methylation to bacterial DNA suggesting one mechanism by which TLRs can sense mitochondrial 
DNA. Recently it was shown that hepatocyte mitochondrial oxidised DNA triggers TLR9 to mediate 
hepatic fibrosis.  
What is ‘’Danger’’ precisely?  It is difficult to define danger in the context of inflammation, but 
DAMPs are generally recognised as intracellularly sequestered molecules hidden from the immune 
system under normal physiological conditions. However, under stressful conditions or tissue trauma 
these are actively released from the cell, exposed on stressed cells or passively released from these 
cells [17]. Here they then bind to cognate TLRs initiating an immune response. It is tacitly assumed 
that these molecules are only released from cells under adverse conditions. There are now multiple 
different DAMPs recognised and none of them seems to share any structural similarities. One of the 
prototypical DAMPs is High Mobility Group Box-1 protein (HMGB-1). HMGB-1 is a nuclear protein 
that can regulate gene expression but can be released extracellularly to elicit responses via TLRS and 
Receptor for advanced Glycation End Products. Interestingly HMGB-1 can be altered by redox status 
also and even monomethylation of HMGB-1 alters its location in the cells [18]. Research into many 
diseases has revealed the importance of DAMPs and their release under a variety of stressors 
including hypoxia for example. A central question is what cell type is the source of the DAMPs in 
SSc? Are these cell types also the source of the autoantigens in SSc? There is clear alterations in 
vascularity in SSc and it has been suggested that the earliest pathologic event is cell death of 
vascular endothelial cells. So an obvious source of DAMPs could be vascular endothelial cells that 
have become apoptotic but have not been cleared appropriately. This reduced ability to clear 
apoptotic cells also occurs in lupus [19]. There is a clear reduced uptake of apoptotic cells by 
macrophages in lupus [20]. This host cell derived DNA inciting stimulation of TLRs requires further 
investigation as the source of DNA in SSc has not been uncovered. 
DAMPs released during ECM remodelling 
Danger molecules can be generated by the ECM. The ECM is comprised of multiple molecules 
including collagen, fibronectin and others. The ECM provides a physical framework between cells 
and tissues and can also act as signalling molecules. These can be altered to produce forms that are 
recognised the TLR system as ‘danger’ to initiate signalling cascades. Coercion of local fibroblasts by 
myofibroblasts activated by DAMPs may propagate the signal resulting in amplification.  
TLR2 and systemic sclerosis  
TLR2 is a membrane bound TLR that responds to gram positive bacterial cell wall components to 
provoke an immune response including lipoproteins of bacteria and mycoplasma. However, 
endogenous ligands such as serum amyloid A have also been identified for TLR2 [21, 22]. TLR2 
recognises its ligands through the formation of a heterodimer with TLR1 or TLR6, these then 
recognise distinct ligands [23]. 
Serum amyloid A is an acute phase protein that is mainly synthesised in the liver and is induced after 
infection or trauma, which can be induced many fold above baseline [24].  
Serum amyloid A has long been known to be associated with acute phase responses and 
inflammation, it is also elevated in SSc [25]. Its role in disease though remained unclear. Our group 
was the first to demonstrate that serum amyloid A activates TLR2 as incubation of recombinant 
protein in TLR4 reporter cells had no effect [26]. Making use of dominant negative NF-KB constructs 
transfected into the cells we could determine that serum amyloid A-mediated induction of 
Interleukin-6 was dependant on NF-KB.  We could then show that the expression level of TLR2 was 
elevated in SSc patients fibroblasts and blockade with a specific TLR2 neutralising antibody 
compared to a isotype control antibody reduced IL-6 levels [26]. IL-6 is critical in mediating pro-
fibrotic effects in dermal fibroblasts via a STAT3-dependant mechanism [27].  
Recently a study has found elevated serum levels of serum amyloid A in SSc patients and confirmed 
our observations of IL-6 being induced in dermal fibroblasts with recombinant protein addition [28], 
interestingly, there was a strong association with high amyloid A levels and pulmonary involvement, 
indicating this could be used as a biomarker. Furthermore TLR2 stimulation leads to increased 
chemotaxis of monocytes via secretion of MCP-2 [29]. Rare genetic variant in TLR2 is associated with 
SSc and higher levels of IL-6 in dendritic cells, which is involved in the fibrotic signalling cascade and 
is associated with pulmonary hypertension.  
Dendritic cells are the sentinals of the immune system sensing the local environment and responding 
appropriatly.  A rare variant in A20, a negative regulator of TLR signalling, is also associated with SSc 
[30]. S100A7 is also elevated in systemic sclerosis [31] and this is a TLR2 ligand. Indeed in bleomycin 
mediated lung fibrosis in pre-clinical studies deletion of TLR2 resulted in reduced inflammation and 
fibrosis [32]. Interestingly, targeting TLR2 with an anti-TLR2 neutralising antibody in the lung fibrosis 
bleomycin model also reduced fibrosis in the lungs with reduced collagen and inflammatory 
mediators but also reduced phosphorylated STAT3 levels [32], which is downstream of IL-6 and 
proved to activate fibroblasts to myofibroblasts [27, 33, 34]. TLR2 stimulation on B cells from SSc 
patients also leads to an upregulation of both pro-inflammatory (IL-6) and pro-fibrotic cytokines such 
as TGF-β1 from these cells which was attenuated by CD19 deletion [35].  
TLR4 and DAMPs 
TLR4 is the best characterised TLR to date and is the receptor for LPS (endotoxin) a constituent 
component of all gram negative bacteria. 
Whilst LPS is the main PAMP that binds TLR4 a number or endogenous danger signals can also bind 
TLR4 to initiate pro-inflammatory signals [36]. Although activated by a wide variety of ligands, many 
of which share no structural similarities, most studies use LPS to activate TLR4. Some of the activator 
of TLR4 signals are directly pro-fibrotic [17, 37]. The list of endogenous ligands for TLR4 is now 
growing rapidly and include heat shock proteins, S100s, high mobility-group box protein 1 (HMGB-1) 
[38, 39], hyalarun [40], fibronectin and tenascin-C [41] (Table 2). Tenascin-C has been shown to 
activate TLR4 in adipocytes and induce ECM remodelling [41]. 
Tenascin-C is an important mediator of arthritis as KO mice are protected from experimental arthritis 
and that it mediates its effects through TLR4 [42]. It is an extracellular matrix component that can be 
in many forms. Recent evidence has suggested that tenascin-C can activate hepatic cells to become 
hepatic stellate cells, the key cells responsible for liver fibrosis. Recently an elegant study confirmed 
a role for tenascin-C in systemic sclerosis with patients having highly elevated levels of the molecule 
compared to controls in both tissue biopsies and also serum [43].  Tenascin-C mediated an increased 
expression of collagen and alpha-smooth muscle actin and this was attenuated by MyD88 blockade 
and TLR4 KO cells, indicating it signals through this pathway as would be expected if TLR4 is the 
receptor. Finally they show that tenascin-C knockout mice are protected from skin and lung fibrosis 
in the bleomycin model with a reduction in lung altered mechanics in KO mice [43]. This activation of 
fibroblasts via tenascin-c and TLR4 appears to involve MyD88 but may also activate the Smad 
pathway indirectly as KO mice had reduced Smad signalling [43].  Smad signalling can be activated by 
TGF-β1 which is induced by bleomycin instillation.  
Fibronectin has also been identified as binding to TLR4, but only fibronectin that contains 
alternatively splice exons encoding type III repeat extra domain (EDA) [44]. Fibronectin in this form is 
recognised by the TLR and immune system. The splicing of fibronectin EDA domains is tightly 
regulated during embryogenesis with human adult tissue devoid of this EDA domain until tissue 
damage occurs. Thus it is used to regulate the generation of tissues and organs and under situations 
of damage is used as an instructive signal to help wound healing. Interestingly recipient-derived 
fibronectin promotes the fibrosis associated with chronic graft rejection and is suggested  to be 
through the enhanced TLR-mediated alterations of T regulatory cells [45].Elevated levels of 
fibronectin EDA has recently been described in SSc serum and also skin [46]. Incubation of fibroblasts 
with this fibronectin EDA resulted in formation of the pathogenic myofibroblast with increased 
collagen and ECM secretion [46]. Furthermore, this was markedly reduced in mice lacking fibronectin 
EDA or TLR4 thus showing the dependence of TLR4 for the fibronectin EDA-mediated increase in 
collagen. This was also blocked with a pharmacological agent blocking TLR4.  It is suggested that the 
initial damage and wound response liberates fibronectin EDA this interacts with TLR4 to initiate 
downstream signalling resulting in a reduction of microRNA29a thus leading to derepression of its 
target: collagen. Stimulation of TLR4 induces fibrosis by augmenting TGF-β signalling [47]. In the 
bleomycin model of fibrosis it was demonstrated that mice without TLR4 compared to wild type 
mice had significantly less fibrosis and this was associated with reduced antibodies and IL-6 [48] and 
SSc tissue has higher levels of TLR4 expression (figure 1). Gene expression analysis after TLR4 
stimulation in fibroblasts leads to global gene changes including a dominance of genes involved in 
wound healing and ECM regulation and as expected changes in inflammatory genes. It maybe 
suggested that spliced fibronectin helps resolve the wound after initial tissue damage by binding to 
expressed TLR4 but a failure of this to cease leads to persistent activation and fibrosis which is 
perpetuated by the plethora of cytokines, chemokines and TIMPs that are released from activated 
myofibroblasts culminating in unrelenting fibrosis (figure 2). TLR4 stimulation in dendritic cells from 
SSc patients also leads to enhanced secretion of the CC chemokine ligand 18 (CCL18) [49]. 
Chemokines are clearly elevated in the sera of SSc patients which will aid leukocyte recruitment to 
the tissue [50]. Figure 3 gives an overview of the possible pathogenic mechanism. 
Internal TLRs 
Intracellular TLRs include TLR3, 7, 8 and 9. These intracellular TLRs are cytosolic sensors for nucleic 
acids normally of viral origin [51]. Such is the importance of intracellular TLRs in promoting 
inflammation to repel viruses that some pathogens have developed mechanisms to manipulate 
them. The localisation of the TLRs is important here in that viruses hijack the host cell and given the 
fact that nucleotides from the host could be potent agonists of these TLRs it is important that these 
are compartmentalised. After stimulation with ligands these TLRs are translocated from the ER to 
the endolysosomes mediated by the ER protein UNC93B1 [52]. However, UNC-93B1 is dispensable 
for ligand recognition and initial signal transduction [52]. Interestingly, mice with a mutation in UNC-
931B suffer from systemic lethal inflammation due to a skewing toward TLR7 trafficking and 
activation and increased Th17 cells and IFN-γ [53]. 
It has been demonstrated that using poly IC, a synthetic dsRNA,  to simulate TLR3 signalling in 
monocytes leads to increased siglec1 expression in SSc [54]. This is important in the binding of 
macrophages to other cell types. TLR3 activation also leads to upregulated endothelin-1; an 
important pro-fibrotic molecule [25]. Furthermore, a polymorphism in TLR3 has been found to be 
associated with idiopathic lung disease with a greater decline in lung function [55]. Also TLR3 KO 
mice has exaggerated lung fibrosis when challenged with bleomycin compared to wild type 
challenged mice suggesting a defect TLR3 signalling system enhances pulmonary fibrosis [55]. We 
have previously found that incubation of SSc monocytes with single stranded RNA leads to 
upregulation of TIMP-1 that ultimately leads to enhanced fibrosis [56]. We could show that 
incubation of patients sera which was eliciting a TLR8-dependant increase in TIMP-1, with an RNA 
degrading enzyme, reduced sera alone-mediated TIMP-1.  
We went on to show that the single stranded RNA-mediated increase in TIMP-1 is dependent on 
MyD88 and also IRAK4 as we used cells from an IRAK-4-deficient patient [56]. It was also 
demonstrated that the TIMP-1 is functional. We postulate that the RNA species in the SSc patient’s 
serum is complexed to autoantibodies that from an RNA-associated autoantibodies aggregate 
leading to TLR mediated fibrosis.   Such changes in self RNA and or DNA being recognised by the 
immune system are common in other autoimmune diseases [57]. Interestingly, single stranded RNA 
is found in many types of virus, suggesting that a viral origin is responsible. We have now 
demonstrated that the single stranded RNA mediates TIMP-1 via TLR8 and depends on 
trimethylation of histone27 which alters the expression of the AP-1 transcription factor Fos-Related 
Antigen-2 (FRA2) [58]. This links possibly viral activation of TLR8 to activation of FRA2 via epigenetic 
modulation by histone methylation [58]. Reduction of FRA2 by small interfering RNA attenuated the 
increased TIMP-1 levels [58]. 
Epstein Barr Virus (EBV) is a herpes DNA virus and evidence has emerged that this may be associated 
with SSc by the fact of serological evidence of infection in SSc patients [59, 60].  It was recently 
found that EBV genes are upregulated in SSc skin biopsies [61]. Furthermore, infection of normal 
dermal fibroblasts or endothelial cells with EBV induced interferon regulatory factors, interferon 
genes and TGF-β,  ultimately leading to expression of ECM proteins and alpha smooth muscle actin  
[61]. Thus EBV may be the initial trigger of SSc. Although direct evidence of EBV viral infection in SSc 
pathogenesis is lacking it maybe that infection on fibroblasts with EBV enables the cell to become 
responsive to growth factors such as TGF-β enabling enhanced proliferation and endowing the cells 
with excessive ECM. Recent work is suggestive of a viral cause however, this is controversial and no 
direct link has been proven. 
Interestingly, gadolinium, a contrast agent, that can cause nephrogenic systemic fibrosis, has been 
shown to activate TLR7 in monocytes ultimately resulting in the release of pro-inflammatory and 
pro-fibrotic mediators [62].  
TLR9 is the receptor that recognises unmethylated CpG motifs in bacterial and viral DNA these 
motifs are prevalent in microbial but not vertebrate genomic DNA and can also recognise 
mitochondrial DNA. DNA II gene deleted mice which breaks down DNA selectively in macrophages 
have an polyarthritis associated with DNA mediated activation [63]. Activation of the TLR9 leads to 
intracellular signalling and an IFN response with IFN regulated genes increased. In IPF it has been 
shown that TLR9 expressing fibroblasts is more prevalent in rapidly progressive patients than slowly  
progressing patients [64] and fibroblasts derived from the rapid progresses were more responsive to 
the TLR9 agonist stimulation and could induce the differentiation of blood CD14+ monocytes to 
fibrocytes that secrete collagen and other ECM molecules [64]. It was also shown that the potent 
pro-fibrotic TGF-β1 leads to upregulation of TLR9 in normal fibroblasts and differentiate into 
myofibroblasts with a persistent and strong expression of α-Sma [65]. These CpG stimulated cells 
both stably expressed α-Sma and PDGFRα, a key receptor for fibrosis generation and an increased 
resistance to apoptosis and reduced caspase-3 levels, possibly mediated through HIF-1α expression 
[65]. In mouse fibroblast it was also shown that CpG stimulation leads to enhanced myofibroblasts 
and cytokine induction and using a wound healing model in mice it was shown that blocking the 
nucleic acid with a third-generation dendrimer reduced granulation tissue [66].  TLR9 gene deleted 
mice are protected from experimental liver fibrosis also suggesting a universal phenomenon [67]. 
Is the TLR system druggable? 
Can we drug the TLR system to modify the pro-fibrotic response to ligands? Small molecule 
inhibitors are now attractive therapies for autoimmune diseases. This is because they are specific 
and generally well tolerated. A challenge has always been to limit unanticipated side effects due to 
inhibition of downstream signalling. Initial excitement for the use of P38 Mitogen-Activated Protein 
Kinase (MAPK) inhibitors was tempered due to unacceptable side effects. Because P38α is such an 
important molecule in inflammation targeting this in archetypal inflammatory diseases such as 
arthritis seemed rationale but orally administered pamapimod in RA failed both to show efficacy 
compared to the comparator methotrexate, importantly also had significantly higher side effects 
including infections, skin disorders and elevated liver enzymes. However, the notion of targeting 
downstream signalling is not dead and many other signalling nodes can be targeted orally.  
Multiple molecules have now been developed that can inhibit and supress TLR signalling.  Inhibiting 
this can occur by blocking the interaction with the DAMP and its receptor, prior to intracellular 
signalling or blocking the internal signalling (table 3).  
There is now a TLR2 blocking antibody manufactured by Opsona therapeutics [68]. This molecule has 
been found to be safe and tolerable and may be of use in SSc where TLR2 activation plays a role in 
myofibroblasts generation [69]. Adaptor proteins MyD88 and Mal could also be therapeutic targets 
and these have been inhibited in rheumatoid arthritis synovial explants in vitro [70], however 
because myD88 is critical in response to microbes it may be that targeting this globally carries an 
increased risk of infection. Recent evidence has also demonstrate that TLR2 mediated fibrosis can be 
blocked in vivo in an animal model by specific ablation of the adaptor protein MyD88 in pericytes 
[71]. Pericytes are suggested with some controversy, to be the precursors to myofibroblasts. It is 
thought that these cells once activated can convert to myofibroblast and secrete ECM; it is 
interesting to note that these cells can be activated by histones; ascribed DAMPs [71]. Therefore, 
this suggests that targeting either TLR2 or MyD88 is effective in attenuating fibrosis. TLR3 has also 
been targeted with CNTO3157 which is a monoclonal antibody that binds TLR3 preventing the 
association of dsRNA and thus inhibits TLR3 mediated effects. CNTO3157 has been shown to 
attenuate the effects of viral challenge on lung function in asthmatic patients [72] 
Emerging evidence suggests that blocking TLR8 can be useful in SSc [17, 37, 58]. Idera 
pharmaceuticals have a TLR7/9 antagonist in clinical trial for plaque psoriasis and also 
dermatomyositis (table 4). AZD1419 is a TLR9 agonist developed by Dynavax that targets the TLR9 
system to modify the immune response in allergic asthma. Another possible therapeutic is to 
sequester the nucleic acids and this has already been done using a third generation dendrimer that 
scavengers nucleic acid and this reduced granulation tissue in an animal model [66]. 
An alternative approach is to target epigenetic modifications that are important in mediating TLR 
signalling. For instance multiple microRNAs, including miR155 [11] are important in negative 
feedback loops to repress signalling and thus altering these could repress TLR signalling and thus 
fibrosis. Use of microRNA mimics would be useful in this situation by binding to the 3’UTR of the 
target mRNAs of proximal effectors [73, 74]. Another approach may be to inhibit histone 
methylation through the use of histone methyltransferase inhibitors such as DZNep targeting 
Enhancer of zeste homologue 2 (Ezh2), which we have shown is effective [58]. EZH2 is a histone 
lysine methyltransferase enzyme mediating the trimethylation onto lysines in the histone H3 and 
thus promotes epigenetic gene silencing.  EZH2 has recently been shown to be critical in the 
generation of Treg cells and their expansion and can govern the life and death of peripheral T cells. 
These data strongly support the idea that epigenetic modification can be targeted to alter TLR 
signalling. However, much like targeting the archetype NF-KB globally, targeting broad TLR 
suppression, may lead to increased infectious disease. Few data are available on targeting histone 
modifications in TLR signalling and may yield more specific inhibitors.  Targeting histone 
methyltransferases as opposed to 5’azacytidine targeting global methylation is likely to have much 
less side effects.  
CRISPR-Cas9 
Clustered, regularly interspaced, short palindromic repeat (CRISPR-Cas9) is a powerful genome 
editing technique. CRISPR is a bacterial adaptive immune mechanism, that can target specific 
sequences of DNA [75]. This consists of unique spacer sequences short repetitive palindromic 
sequences and sequences encoding Cas proteins. It is a type of immune mechanism present in 
bacteria to protect them from viral infection [76]. The system has been engineered so that a 
guideRNA (gRNA) with the Cas9 that specifically cleaves DNA activating doubles stand break repair 
machinery, this includes nonhomologous end-joining and homology directed repair.  As an RNA-
guided DNA endonuclease, Cas9 can easily be programmed to target new sites by altering its guide 
RNA sequence. This has made sequence specific gene editing much easier. This techniques has been 
used to genome edit in cells in vitro and in vivo in mice to genetically remove sequences [77]. This 
new technique with far reduced ‘’off target’’ effects could be used to precisely genome edit the TLR 
system. This could be used to permanently ablate either the TLR or a downstream effector. CRISPR-
Cas9 can also be used to introduce a mutation as opposed to deletion of the gene and this could for 
instance in the case of TLR4 induce tolerance thus reducing the immune response. 
Conclusion 
Recent literature has now well established the role of TLRs in systemic sclerosis pathogenesis 
through the activation of their receptors to downstream signalling and resulting release of pro-
fibrotic molecules. Indeed, in normal fibroblasts activation of TLRs, normally expressed at a low 
level, can result in fibrosis independent of inflammatory cells.  The accumulating data that support 
the involvement of these receptors in fibrosis are fuelling efforts to target these. The importance of 
their involvement in SSc pathogenesis suggests that they a tractable target and various molecules 
can inhibit these TLRs and appears successful in animal models. This now requires further study and 
areas such as long non coding RNAs that regulate TLR signalling by altering chromatin state [78] 
could be new therapeutic targets. New technologies enabling identification of epigenetic modifiers 
will expose these as regulators of TLR signalling and such epigenetic changes being rapid may explain 
tolerance induction to TLR ligands. Finally, a breakdown between the equilibrium between us and 
the microbiome may also be responsible for the autoimmunity. 
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Figure legend 
Figure 1 Elevated TLR4 in SSc skin biopsies. Mean levels of TLR4 in SSc skin biopsies measured by 
qPCR data is normalised to the house keeping gene 18S and shown as fold change compared to 
control skin biopsies. Data is the mean and standard deviation.  
 
 
 
Figure 2 Possible pathway through which DAMPs trigger fibrosis via TLR4. TLR4 is activated by 
DAMPs which are released passively after tissue trauma this leads to activation of the signalling 
pathways leading to pro-fibrotic cytokine release including Interleukins, this activates the fibroblasts 
to transition to the myofibroblast; the chief cell in fibrosis. 
  
Figure 3 Possibly pro fibrotic pathways in SSc. 
 
 
  
 Table 1 Cell types in SSc skin 
Cell Type TLR expression 
Fibroblasts  + 
Pericytes + 
Macrophages +++ 
Dendritic cells ++++ 
T cells + 
+= low expression 
 
 
 
 
Table 2 TLRs and their known endogenous ligands 
 
TLR 
 
Endogenous ligand 
 
TLR2 HMGB-1  
 Serum amyloid-A  
 Snapin A 
 
 
TLR3 mRNA 
 
 
TLR4 HMGB-1  
 HSP-20, -60, -70, -96  
 Fibrinogen  
 Extra domain A of Fibronectin  
 Tenascin C  
 Surfactant protein-A 
S100A8/9, CD138 
 
 
TLR6/2 Soluble tuberculosis factor  
 HSP-60, -70, -96 
 
 
TLR7 ssRNA (immune complexes) 
 
 
TLR8 ssRNA (immune complexes), human cardiac myosin 
 
 
TLR9 DNA (immune complexes)  
 
 
 
Table 3 Ways of interfering with TLR signalling 
Blocking exogenous ligand/TLR interaction 
Blocking the TLR directly with an antibody 
Inhibiting downstream signalling with small molecule inhibitors such as MyD88 
Enhancing negative regulators of the TLR signalling pathway 
Modifying epigenetic regulators of the TLR pathways such as microRNAs 
 
 
Table 4 Current conditions with TLR7/8/9 antagonists under consideration 
Plaque Psoriasis 
Dermatomyositis 
B-cell lymphoma 
 
